REPL

Replimune Group is moving higher today following the major announcement that the company has reached an agreement with the U.S. Food and Drug Administration to resubmit the marketing application for its experimental melanoma drug, RP1. This development marks a significant turnaround for the company, as it prepares for a third attempt at approval following two previous rejections that were largely attributed to concerns over study design. The positive sentiment surrounding this regulatory path forward continues to drive investor interest, building on the momentum from the company's substantial rally in the previous session. The stock remains roughly flat in after-hours trading as investors digest the implications of this renewed regulatory opportunity.